PRRT2 and acute lymphoblastic leukemia: We have also recently shown that the pre-treatment of MSC with typical and novel chimeric peptide PKC inhibitors, prior to the establishment of co-cultures, renders B-ALL cell lines and primary B-ALL cells more susceptible to treatment with dexamethasone (DEXA) [16].